| Balance sheet (USD) | Q3 2026 ended Mar 31, 2026 | Q2 2026 ended Dec 31, 2025 | Q1 2026 ended Sep 30, 2025 | Q4 2025 ended Jun 30, 2025 | Q3 2025 ended Mar 31, 2025 | Q2 2025 ended Dec 31, 2024 | Q1 2025 ended Sep 30, 2024 | Q4 2024 ended Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.21M | 5.15M | 1.13M | 1.56M | 2.54M | 3.96M | 3.87M | 4.80M |
| Total current assets | 3.38M | 5.30M | 1.25M | 1.67M | 2.73M | 4.07M | 4.04M | 4.97M |
| Property, plant and equipment | 6.53M | 6.66M | 6.79M | 6.83M | 6.98M | 7.17M | 7.37M | 7.51M |
| Goodwill and intangibles | 310.8K | 312.9K | 315.0K | 317.0K | 319.1K | 321.2K | 323.2K | 325.3K |
| Total assets | 10.22M | 12.27M | 8.36M | 8.82M | 10.03M | 11.57M | 11.74M | 12.82M |
| Total current liabilities | 1.07M | 1.20M | 1.18M | 1.31M | 1.20M | 1.18M | 1.63M | 1.36M |
| Total liabilities | 1.10M | 1.20M | 1.20M | 1.30M | 1.20M | 1.20M | 1.63M | 1.36M |
| Retained earnings | -154.84M | -152.85M | -150.63M | -148.84M | -146.75M | -144.53M | -142.50M | -139.37M |
| Shareholders' equity | 9.15M | 11.07M | 7.17M | 7.52M | 8.83M | 10.39M | 10.11M | 11.46M |
From Nanoviricides, Inc.'s 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read balance sheet or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.